Immune checkpoint modulators

CCT244747 is a potent, orally bioavailable and highly selective CHK1 inhibitor, with an IC 50 of 7.7 nM: CCT244747 also abrogates G2 checkpoint with an IC 50 of 29 nM.In VitroCCT244747 poorly inhibits CHK2 (IC 50 &gt:10 μM) and CDK1 (IC 50 &gt:10

Cemiplimab is a monoclonal IgG4 antibody with high affinity for programmed death receptor-1 (PD-1) that blocks PD-1/PD-L1 mediated T cell inhibition. It is commonly used in squamous cell skin cancer research.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin

Cemiplimab is a monoclonal IgG4 antibody with high affinity for programmed death receptor-1 (PD-1) that blocks PD-1/PD-L1 mediated T cell inhibition. It is commonly used in squamous cell skin cancer research.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin

Cemiplimab is a monoclonal IgG4 antibody with high affinity for programmed death receptor-1 (PD-1) that blocks PD-1/PD-L1 mediated T cell inhibition. It is commonly used in squamous cell skin cancer research.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin

Cemiplimab is a monoclonal IgG4 antibody with high affinity for programmed death receptor-1 (PD-1) that blocks PD-1/PD-L1 mediated T cell inhibition. It is commonly used in squamous cell skin cancer research.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin

Durvalumab is an humanized anti-PD-L1 monoclonal antibody, completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin Level&lt:0.01EU/μg.

Durvalumab is an humanized anti-PD-L1 monoclonal antibody, completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin Level&lt:0.01EU/μg.

Durvalumab is an humanized anti-PD-L1 monoclonal antibody, completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin Level&lt:0.01EU/μg.

Durvalumab is an humanized anti-PD-L1 monoclonal antibody, completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively.Purity&gt:95% (SDS-PAGE&amp:SEC)Endotoxin Level&lt:0.01EU/μg.

GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignanciesIn VitroMEK inhibition either by pharmacologic inhibitors or RNAi-mediated gene silencing

GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignanciesIn VitroMEK inhibition either by pharmacologic inhibitors or RNAi-mediated gene silencing

GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignanciesIn VitroMEK inhibition either by pharmacologic inhibitors or RNAi-mediated gene silencing